Lightnews — Scholar-powered news

Steven Artandi @stevenartandi.bsky.social · Aug 25

SCI member Lawrence Recht & others found that in IDH-mutant gliomas, adjuvant radiation (aXRT) given within 3 months of diagnosis did not improve survival compared to deferred radiation (dXRT). pubmed.ncbi.nlm.nih.gov/40513058/

1 2

Steven Artandi @stevenartandi.bsky.social · Aug 22

SCI member @lindakachuri.bsky.social and colleagues show that adding #polygenic risk scores to multimodal classifiers improves molecular subtyping before surgery. The approach enhanced prediction of isocitrate dehydrogenase mutation status in #glioma patients. www.nature.com/articles/s41...

4

Steven Artandi @stevenartandi.bsky.social · Aug 20

SCI member Ovijit Chaudhuri and colleagues found that matrix stiffness and stress relaxation mediate monocyte migration, revealing how monocytes use actin-driven pushing forces at the leading edge to create migration paths in confining viscoelastic matrices. www.pnas.org/doi/10.1073/...

Steven Artandi @stevenartandi.bsky.social · Aug 18

SCI member Erinn Rankin & others show FTO, an RNA demethylase, drives glutamine reprogramming in #ccRCC, promoting growth. Inhibiting FTO disrupts metabolism, > DNA damage, and reduces survival, but pyrimidines/antioxidants rescue, highlighting FTO as a target. pubmed.ncbi.nlm.nih.gov/40532011/

1 2

Steven Artandi @stevenartandi.bsky.social · Aug 15

SCI member Robert West & others found #DCIS comprises multiple genetic clones with significant phenotypic diversity and linked alterations in epithelial cell states and basement membrane integrity with invasive breast cancer progression.
aacrjournals.org/cancerres/ar...

1 2

Steven Artandi @stevenartandi.bsky.social · Aug 13

SCI members and others found radiotherapy increases immunosuppressive VISTA+ myeloid cells in head and neck cancer's microenvironment. VISTA blockade boosts #radiotherapy efficacy by promoting antitumor myeloid activity and T cell responses in multiple cancer models.
www.cell.com/cell-reports...

1

Steven Artandi @stevenartandi.bsky.social · Aug 11

SCI members found GPT-RadPlan, an AI-driven treatment planning framework, outperformed or matched human experts in prostate and head & neck cancer plans, improving target coverage and reducing organ-at-risk doses by 5 Gy, all with no extra training required. iopscience.iop.org/article/10.1...

1

Steven Artandi @stevenartandi.bsky.social · Aug 8

Gao lab created an ML-guided workflow to deimmunize human protein domains for safer #GeneTherapy. They built zinc fingers and drug-controllable transcription factors to target genes like UTRN and SCN1A. www.sciencedirect.com/science/arti... @synbiogaolab.bsky.social‬ #AIandCancer

2

Steven Artandi @stevenartandi.bsky.social · Aug 6

SCI member Claudia Petritsch & others found that immune checkpoint blockade, typically ineffective on its own in high-grade #glioma, can become a powerful treatment when combined with BRAF/MEK inhibition in BRAFV600E-mutant high-grade glioma. www.cell.com/cell-reports...

1 1

Steven Artandi @stevenartandi.bsky.social · Aug 1

I am proud to share that U.S. News & World Report has ranked @StanfordHealth among the top ten #CancerHospitals in the nation. This ranking reflects our team's commitment to excellence across research, clinical innovation, and #PatientCare. med.stanford.edu/cancer/about... @usnews.com #CancerCare

1 3

Steven Artandi @stevenartandi.bsky.social · Jul 31

SCI member Haruka Itakura and others developed an MRI-based model to predict survival risk in #TNBC patients, identifying high-risk groups with a 25% 5-year survival gap using a 50-gene signature. The tool showed strong accuracy and clinical potential. www.nature.com/articles/s41...

Steven Artandi @stevenartandi.bsky.social · Jul 30

SCI member Edward Graves & others developed a method to enhance the effectiveness of hypoxia-targeted drugs in solid tumors.

www.researchgate.net

Steven Artandi @stevenartandi.bsky.social · Jul 28

SCI member Edgar Engleman & team found tumors use erythropoietin (EPO) to block immune attack. In #LiverCancer models, tumor EPO reprograms macrophages via EPOR to create a T cell-poor environment. Blocking the EPO/EPOR axis reactivates immunity & shrinks tumors. pubmed.ncbi.nlm.nih.gov/40273234/

Steven Artandi @stevenartandi.bsky.social · Jul 25

SCI member Allison Kurian & others found that nearly half of #BreastCancer patients continue endocrine therapy beyond 5 years. The study emphasizes the importance of shared decision-making. academic.oup.com/jnci/advance...

Steven Artandi @stevenartandi.bsky.social · Jul 23

Alexa Pohl & others found that transportation insecurity negatively impacted #BreastaCancerScreening, while social support positively affected colorectal and #BreastCancer screening. No interaction was found between social support and transportation insecurity. jamanetwork.com/journals/jam...

1

Steven Artandi @stevenartandi.bsky.social · Jul 23

By uniting the innovative research efforts of Stanford Medicine and UCSF and drawing from the lessons of past successes, we can propel toward a future where cancer is no longer a formidable foe. @stanfordmedicine.bsky.social @ucsfcancer.bsky.social

Stanford Cancer Institute @stanford-cancer.bsky.social · Jul 23

A visionary $100 million matching grant from the Weill Family Foundation is bringing together @stanfordmedicine.bsky.social & @ucsfcancer.bsky.social to launch the Weill Cancer Hub West – an innovative collaboration that will transform #CancerResearch and care. med.stanford.edu/news/all-new...

1 3

Steven Artandi @stevenartandi.bsky.social · Jul 21

Stanford postdoc Minji Jung & SCI members found #KidneyCancer survivors had a higher rate of depression and anxiety, especially during the early phase following diagnosis, compared with the noncancer population. aacrjournals.org/cebp/article...

1

Steven Artandi @stevenartandi.bsky.social · Jul 18

A weekly symptom-assessment intervention led by trained lay health workers may help reduce acute care use and improve #EndOfLifeCare for older adults with cancer, according to SCI member Manali Patel.

Symptom-assessment intervention may improve care, reduce costs for older adults with cancer

CHICAGO — A weekly symptom-assessment intervention led by trained lay health workers may help reduce acute care use and improve end-of-life care for older adults with cancer, according to data…

www.healio.com

2

Steven Artandi @stevenartandi.bsky.social · Jul 14

Post doc @jkim-1003.bsky.social & others found #AI natural language processing–enabled analysis of patient messages can generate valuable research topics that prioritize patient perspectives in #CancerCare, guiding future patient-centered health research. jamanetwork.com/journals/jam...

1 1

Steven Artandi @stevenartandi.bsky.social · Jul 11

SCI member Sydney Lu & others found mutations in RNA splicing factors drive mis-spliced mRNA isoforms in cancers. They identified neoantigens from splicing alterations in #leukemia, showing TCR-engineered T cells target these mutations. pubmed.ncbi.nlm.nih.gov/40273911/

Steven Artandi @stevenartandi.bsky.social · Jul 9

SCI member @johnleppert.bsky.social‬ & others review the challenge of managing small renal masses, urging caution over reflexive treatment. Drawing lessons from low-risk #ProstateCancer, they propose the TOP model to reduce overtreatment. pubmed.ncbi.nlm.nih.gov/40447472/

1

Steven Artandi @stevenartandi.bsky.social · Jul 7

SCI member Paul Mischel & others found that #ecDNA drives evolution & heterogeneity in urothelial carcinoma, playing an early role in tumorigenesis. The study highlights immune evasion mechanisms linked to ecDNA, offering insights for developing targeted therapies. pubmed.ncbi.nlm.nih.gov/40331621/

1

Steven Artandi @stevenartandi.bsky.social · Jul 3

Saurabh Dahiya showed 87% response and 78% complete remission in hard-to-treat #LBCL with low severe side effects. Early ASCO 2025 data suggest dual CD19/CD20 CAR-T could be a powerful new option. www.cgtlive.com/view/cd19-20... #ASCO25

CD19/20-Targeted KITE-363 Elicits Strong Response in LBCL

KITE-363 shows promising results in treating relapsed/refractory large B-cell lymphoma, with high response rates and manageable adverse events.

www.cgtlive.com

Steven Artandi @stevenartandi.bsky.social · Jun 30

SCI member Seung Kim & others found that stromal KITL in the pancreas restrains tumor progression. Downregulation of KITL during tumorigenesis promotes cancer. KITL signaling may offer potential for cancer prevention without disrupting tissue homeostasis. pubmed.ncbi.nlm.nih.gov/39918337/

Steven Artandi @stevenartandi.bsky.social · Jun 27

SCI member Joel Neal & others found mobocertinib is not superior to platinum-based chemotherapy in treating EGFR ex20ins+ advanced/metastatic #NSCLC. No significant difference in progression-free survival, but mobocertinib showed longer response duration. pubmed.ncbi.nlm.nih.gov/39879577/